These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 21957170)

  • 21. Glutamatergic influences on the basal ganglia.
    Greenamyre JT
    Clin Neuropharmacol; 2001; 24(2):65-70. PubMed ID: 11307040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glutamatergic mechanisms in different disease states: overview and therapeutical implications -- an introduction.
    Tzschentke TM
    Amino Acids; 2002; 23(1-3):147-52. PubMed ID: 12373529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Glutamate antagonists in neurology].
    Block F; Kosinski CM
    Nervenarzt; 2001 Jun; 72(6):393-405. PubMed ID: 11433698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches.
    de Bartolomeis A; Latte G; Tomasetti C; Iasevoli F
    Mol Neurobiol; 2014 Feb; 49(1):484-511. PubMed ID: 23999870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated excitatory neurotransmitter levels in the fibromyalgia brain.
    Harris RE
    Arthritis Res Ther; 2010; 12(5):141. PubMed ID: 20959024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The neurometabolic profiles of GABA and Glutamate as revealed by proton magnetic resonance spectroscopy in type 1 and type 2 diabetes.
    d'Almeida OC; Violante IR; Quendera B; Moreno C; Gomes L; Castelo-Branco M
    PLoS One; 2020; 15(10):e0240907. PubMed ID: 33120406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Glutamatergic conception of mood disorders].
    Permoda-Osip A; Rybakowski J
    Psychiatr Pol; 2011; 45(6):875-88. PubMed ID: 22335130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Review of Molecular Imaging of Glutamate Receptors.
    Kim JH; Marton J; Ametamey SM; Cumming P
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overcoming Translational Barriers in Acute Kidney Injury: A Report from an NIDDK Workshop.
    Zuk A; Palevsky PM; Fried L; Harrell FE; Khan S; McKay DB; Devey L; Chawla L; de Caestecker M; Kaufman JS; Thompson BT; Agarwal A; Greene T; Okusa MD; Bonventre JV; Dember LM; Liu KD; Humphreys BD; Gossett D; Xie Y; Norton JM; Kimmel PL; Star RA
    Clin J Am Soc Nephrol; 2018 Jul; 13(7):1113-1123. PubMed ID: 29523680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glutamatergic hypothesis of schizophrenia: involvement of Na+/K+-dependent glutamate transport.
    Nanitsos EK; Nguyen KT; St'astný F; Balcar VJ
    J Biomed Sci; 2005 Dec; 12(6):975-84. PubMed ID: 16228297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurobiology, Functions, and Relevance of Excitatory Amino Acid Transporters (EAATs) to Treatment of Refractory Epilepsy.
    Zaitsev AV; Smolensky IV; Jorratt P; Ovsepian SV
    CNS Drugs; 2020 Nov; 34(11):1089-1103. PubMed ID: 32926322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glutamatergic Signaling in the Central Nervous System: Ionotropic and Metabotropic Receptors in Concert.
    Reiner A; Levitz J
    Neuron; 2018 Jun; 98(6):1080-1098. PubMed ID: 29953871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glutamate as a neurotransmitter in the healthy brain.
    Zhou Y; Danbolt NC
    J Neural Transm (Vienna); 2014 Aug; 121(8):799-817. PubMed ID: 24578174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of the glutamatergic system in pathophysiology and pharmacotherapy for depression: preclinical and clinical data].
    Paslakis G; Gass P; Deuschle M
    Fortschr Neurol Psychiatr; 2011 Apr; 79(4):204-12. PubMed ID: 21117011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Astroglia, Glutamatergic Transmission and Psychiatric Diseases.
    Verkhratsky A; Steardo L; Peng L; Parpura V
    Adv Neurobiol; 2016; 13():307-326. PubMed ID: 27885635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glutamatergic Dysfunction and Synaptic Ultrastructural Alterations in Schizophrenia and Autism Spectrum Disorder: Evidence from Human and Rodent Studies.
    Eltokhi A; Santuy A; Merchan-Perez A; Sprengel R
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glutamate: a truly functional amino acid.
    Brosnan JT; Brosnan ME
    Amino Acids; 2013 Sep; 45(3):413-8. PubMed ID: 22526238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases.
    Li SH; Abd-Elrahman KS; Ferguson SSG
    Pharmacol Ther; 2022 Nov; 239():108275. PubMed ID: 36038019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glutamate and Brain Glutaminases in Drug Addiction.
    Márquez J; Campos-Sandoval JA; Peñalver A; Matés JM; Segura JA; Blanco E; Alonso FJ; de Fonseca FR
    Neurochem Res; 2017 Mar; 42(3):846-857. PubMed ID: 28012058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glutamate as a therapeutic target in psychiatric disorders.
    Javitt DC
    Mol Psychiatry; 2004 Nov; 9(11):984-97, 979. PubMed ID: 15278097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.